ABOUT RVO

RVO Is the Second Most Common Cause of Blindness Due to
Retinal Vascular Disease1

RVO can be an acute or chronic condition that may be associated with serious systemic disease2-4

Typical age

Other risk factors

>50-year incidence increase with age2,3

Hypertension, diabetes, atherosclerosis,
CV disease, smoking
2-4

Overexpression of ocular VEGF mediates destructive pathology in RVO5,6

  • Stagnation of venous blood flow following occlusion leads to oxygen depletion and hypoxia5,6
  • Vascular damage stimulates overexpression of VEGF, leading to angiogenesis and associated macular edema5,6
  • Intraocular VEGF levels are correlated with disease severity and vision loss7,8

Systemic VEGF plays multiple roles in cellular functions, such as angiogenesis and tissue repair9,10

  • Complications attributed to decreased systemic VEGF levels include hypertension, ATEs, renal dysfunction, and wound complications10
ATE, arterial thromboembolic event; CV, cardiovascular; RVO, retinal vein occlusion; VEGF, vascular endothelial growth factor.

 

References: 1. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33:111-131. 2. Yanoff M, Duker JS, eds. Ophthalmology. 2nd ed. St. Louis, MO: Mosby, Inc.; 2004. 3. Klein R, Moss SE, Meuer SM, Klein BEK. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126:513-518. 4. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol. 2006;124:726-732. 5. Ferrara N. Vascular endothelial growth factor. Trends Cardiovasc Med. 1993;3:244-250. 6. Lu M, Adamis AP. Molecular biology of choroidal neovascularization. Ophthalmol Clin N Am. 2006;19:323-334. 7. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye. 2008;22;42-48. 8. Noma H, Funatsu H, Mimura T, et al. Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular oedema and central retinal vein occlusion. Acta Ophthalmol. 2010;88:646-651. 9. Wirostko B, Wong TY, Rafael Simo. Vascular endothelial growth factor and diabetic complications. Progress in Retinal and Eye Research. 2008;27:608-621. 10. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 2009;6:465-477.